Validation of the mIBG skeletal SIOPEN scoring method in two independent high-risk neuroblastoma populations: the SIOPEN/HR-NBL1 and COG-A3973 trials
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11130%2F18%3A10375408" target="_blank" >RIV/00216208:11130/18:10375408 - isvavai.cz</a>
Alternative codes found
RIV/00064203:_____/18:10375408
Result on the web
<a href="https://doi.org/10.1007/s00259-017-3829-7" target="_blank" >https://doi.org/10.1007/s00259-017-3829-7</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1007/s00259-017-3829-7" target="_blank" >10.1007/s00259-017-3829-7</a>
Alternative languages
Result language
angličtina
Original language name
Validation of the mIBG skeletal SIOPEN scoring method in two independent high-risk neuroblastoma populations: the SIOPEN/HR-NBL1 and COG-A3973 trials
Original language description
Background Validation of the prognostic value of the SIOPEN mIBG skeletal scoring system in two independent stage 4, mIBG avid, high-risk neuroblastoma populations. Results The semi-quantitative SIOPEN score evaluates skeletal meta-iodobenzylguanidine (mIBG) uptake on a 0-6 scale in 12 anatomical regions. Evaluable mIBG scans from 216 COG-A3973 and 341 SIOPEN/HR-NBL1 trial patients were reviewed pre- and post-induction chemotherapy. The prognostic value of skeletal scores for 5-year event free survival (5 yr.-EFS) was tested in the source and validation cohorts. At diagnosis, both cohorts showed a gradual non-linear increase in risk with cumulative scores. Several approaches were explored to test the relationship between score and EFS. Ultimately, a cutoff score of <= 3 was the most useful predictor across trials. A SIOPEN score <= 3 pre-induction was found in 15% SIOPEN patients and in 22% of COG patients and increased post-induction to 60% in SIOPEN patients and to 73% in COG patients. Baseline 5 yr.-EFS rates in the SIOPEN/HR-NBL1 cohort for scores <= 3 were 47% +/- 7% versus 26% +/- 3% for higher scores at diagnosis (p < 0.007) and 36% +/- 4% versus 14% +/- 4% (p < 0.001) for scores obtained post-induction. The COG-A3973 showed 5 yr.-EFS rates for scores <= 3 of 51% +/- 7% versus 34% +/- 4% for higher scores (p < 0.001) at diagnosis and 43% +/- 5% versus 16% +/- 6% (p = 0.004) for post-induction scores. Hazard ratios (HR) significantly favoured patients with scores <= 3 after adjustment for age and MYCN-amplification. Optimal outcomes were recorded in patients who achieved complete skeletal response. Conclusions Validation in two independent cohorts confirms the prognostic value of the SIOPEN skeletal score. In particular, patients with an absolute SIOPEN score > 3 after induction have very poor outcomes and should be considered for alternative therapeutic strategies.
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30224 - Radiology, nuclear medicine and medical imaging
Result continuities
Project
—
Continuities
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace
Others
Publication year
2018
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
European Journal of Nuclear Medicine & Molecular Imaging
ISSN
1619-7070
e-ISSN
—
Volume of the periodical
45
Issue of the periodical within the volume
2
Country of publishing house
DE - GERMANY
Number of pages
14
Pages from-to
292-305
UT code for WoS article
000418963400017
EID of the result in the Scopus database
2-s2.0-85029741165